Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study

INTRODUCTION: Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Li, Qian, Jiang, Huiqin, Li, Hong, Xu, Ruihua, Shen, Lin, Yu, Yiyi, Wang, Yan, Cui, Yuehong, Li, Wei, Yu, Shan, Liu, Tianshu
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226611/
https://ncbi.nlm.nih.gov/pubmed/27409420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10456
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados